EUVIMEDEUVIMED entdecken
Kohortenstudie

Glucagon‐Like Peptide‐1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study

Wajd Alkabbani iD, Salvatore Crisafulli, Julie M Paik, Ali Tavakkoli iD, Katsiaryna Bykov, Robert J Glynn, Deborah J Wexler, Elisabetta Patorno iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70963 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Wajd Alkabbani und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Gastrointestinal Motility, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Patient-Centered Outcomes Research Institute (PCORI), FDA HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Evidence showing the association between glucagon‐like 1 (GLP‐1) based therapies and severe gastrointestinal motility events is limited and possible treatment effect heterogeneity by demographic and clinical characteristics is unknown. We aimed to compare rates of severe motility‐related gastrointestinal adverse events between initiators of GLP‐1 based therapies versus sodium‐glucose co‐transporter 2 inhibitors (SGLT‐2i). Materials and Methods This new‐user active ‐ comparative cohort study used two de‐identified US commercial healthcare databases to identify adults with type‐2 diabetes without a prior history of major gastrointestinal conditions who initiated GLP‐1 based therapies (GLP‐1 receptor agonists or tirzepatide) or SGLT‐2i. The main outcome was a composite of severe constipation, gastroparesis, and gastrointestinal obstruction. We estimated incidence rates, hazard ratios (HRs), and 95% confidence intervals (CIs) after propensity score matching.

Results

Among 313 342 matched pairs of GLP‐1 based therapies and SGLT‐2i initiators (mean age 60 years; 45% female), followed on treatment for a median of 5.2 months, incidence rates of the composite outcome were 1.02 among GLP‐1 based therapies versus 0.75 among SGLT‐2i initiators per 100 person‐years. The risk was higher among GLP‐1 based therapies versus SGLT‐2i initiators (rate difference 0.27 per 100 person‐years; HR 1.37, 95% CI 1.30, 1.45) for the composite event and each individual component. This relative increased risk was consistent across subgroups stratified by GLP‐1 based therapies agent, age, sex, BMI, frailty level, diabetes severity, or opioid use.

Conclusions

The absolute risk of motility‐related gastrointestinal adverse events was 1% or less but was higher among initiators of GLP‐1 based therapies compared to SGLT‐2i. These findings can inform the risk benefit assessment by clinicians before initiating these treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide 1Gastrointestinal MotilitySodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsGastrointestinal DiseasesGastroparesisHumansFemaleMaleMiddle AgedGlucagon-Like Peptide-1 Receptor AgonistsCohort StudiesTirzepatideAgedConstipationIncidenceIncretinsUnited States

Stichwörter der Autor:innen

GLP‐1 analogueantidiabetic drugcohort studypharmaco‐epidemiologyreal‐world evidence

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1Sodium-Glucose Transporter 2 InhibitorsTirzepatideHypoglycemic AgentsIncretins

Autor:innen und Institutionen

  • School of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada.
  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
  • Division of Renal (Kidney) Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • New England Geriatric Research Education and Clinical Center, VA Boston Healthcare System, Boston, Massachusetts, USA.
  • Division of General and GI Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Wajd Alkabbani, Ali Tavakkoli, Elisabetta Patorno

Förderung

  • Patient-Centered Outcomes Research Institute (PCORI)
  • FDA HHS
  • NIDDK NIH HHS
  • NIA NIH HHS
  • Food and Drug Administration
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute on Aging

Zitieren

APA

Alkabbani, W., Crisafulli, S., Paik, J. M., Tavakkoli, A., Bykov, K., Glynn, R. J., Wexler, D. J., & Patorno, E. (2026). Glucagon‐Like Peptide‐1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70963

Vancouver

Alkabbani W, Crisafulli S, Paik JM, Tavakkoli A, Bykov K, Glynn RJ, et al. Glucagon‐Like Peptide‐1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70963

BibTeX
@article{Alkabbani2026,
  author = {Alkabbani, Wajd and Crisafulli, Salvatore and Paik, Julie M and Tavakkoli, Ali and Bykov, Katsiaryna and Glynn, Robert J and Wexler, Deborah J and Patorno, Elisabetta},
  title = {Glucagon‐Like Peptide‐1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70963}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche